KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) Preferred Dividend Payments (2017 - 2021)

Historic Preferred Dividend Payments for Arbutus Biopharma (ABUS) over the last 5 years, with Q4 2021 value amounting to $574000.0.

  • Arbutus Biopharma's Preferred Dividend Payments fell 8162.02% to $574000.0 in Q4 2021 from the same period last year, while for Sep 2022 it was $574000.0, marking a year-over-year decrease of 9609.2%. This contributed to the annual value of $12.1 million for FY2021, which is 13.2% up from last year.
  • Arbutus Biopharma's Preferred Dividend Payments amounted to $574000.0 in Q4 2021, which was down 8162.02% from $5.1 million recorded in Q3 2021.
  • In the past 5 years, Arbutus Biopharma's Preferred Dividend Payments ranged from a high of $5.1 million in Q3 2021 and a low of $574000.0 during Q4 2021
  • Its 5-year average for Preferred Dividend Payments is $2.7 million, with a median of $2.8 million in 2019.
  • Per our database at Business Quant, Arbutus Biopharma's Preferred Dividend Payments skyrocketed by 19055.98% in 2018 and then crashed by 8162.02% in 2021.
  • Arbutus Biopharma's Preferred Dividend Payments (Quarter) stood at $911000.0 in 2017, then surged by 190.56% to $2.6 million in 2018, then grew by 8.8% to $2.9 million in 2019, then increased by 8.44% to $3.1 million in 2020, then tumbled by 81.62% to $574000.0 in 2021.
  • Its Preferred Dividend Payments stands at $574000.0 for Q4 2021, versus $5.1 million for Q3 2021 and $3.3 million for Q2 2021.